Skip to Main Content

Paper Details

Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
Neuro Oncol
8
2022
AZD6244, Children, Pediatric Brain Tumor, Pediatric Low Grade Glioma, Selumetinib
Author NameAffiliation
Jason FangusaroAnn & Robert H. Lurie Children's Hospital of Chicago
Tina Young PoussaintChildren's Hospital Boston
Azra H LigonBrigham and Women's Hospital
Anuradha BanerjeeUniversity of California san francisco
Roger J Packer
Roger J Packer
Lindsay Kilburn
Lindsay Kilburn
Ian F PollackPittsburgh Children's Hospital
Ian F PollackPittsburgh Children's Hospital
Paul G FisherStanford University
Girish DhallChildren's Hospital Los Angeles
Patricia BaxterTexas Children's Cancer Center, Baylor College of Medicine
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Maryam FouladiCincinnati Children's Hospital Medical Center
  • 1 - 16

Datasets

Release 1.2